{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:29:57Z","timestamp":1791772197237,"version":"4.3.4"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00415-025-12941-4","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T12:18:52Z","timestamp":1739621932000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and safety of 4-aminopyridine in episodic ataxia type 2: a case series"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5301-8621","authenticated-orcid":false,"given":"Lorenzo","family":"Verriello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giada","family":"Pauletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarosaria","family":"Valente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"issue":"3","key":"12941_CR1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/S0092-8674(00)81373-2","volume":"87","author":"RA Ophoff","year":"1996","unstructured":"Ophoff RA, Terwindt GM, Vergouwe MN, van Eijk R, Oefner PJ, Hoffman SMG et al (1996) Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell N 87(3):543\u2013552","journal-title":"Cell N"},{"issue":"2","key":"12941_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.nurt.2007.01.014","volume":"4","author":"M Strupp","year":"2007","unstructured":"Strupp M, Zwergal A, Brandt T (2007) Episodic ataxia type 2. Neurotherapeutics 4(2):267\u2013273","journal-title":"Neurotherapeutics"},{"issue":"10","key":"12941_CR3","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1093\/brain\/awm126","volume":"130","author":"JC Jen","year":"2007","unstructured":"Jen JC, Graves TD, Hess EJ, Hanna MG, Griggs RC, Baloh RW (2007) Primary episodic ataxias: diagnosis, pathogenesis and treatment. Brain 130(10):2484\u20132493","journal-title":"Brain"},{"issue":"1","key":"12941_CR4","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1212\/01.WNL.0000101675.61074.50","volume":"62","author":"J Jen","year":"2004","unstructured":"Jen J, Kim GW, Baloh RW (2004) Clinical spectrum of episodic ataxia type 2. Neurology 62(1):17\u201322","journal-title":"Neurology"},{"issue":"9","key":"12941_CR5","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1074\/jbc.M110948200","volume":"277","author":"E Wappl","year":"2002","unstructured":"Wappl E, Koschak A, Poteser M, Sinnegger MJ, Walter D, Eberhart A et al (2002) Functional consequences of P\/Q-type Ca2+Channel Cav2.1 Missense Mutations Associated with Episodic Ataxia Type 2 and Progressive Ataxia. J Biological Chem 277(9):6960\u20136966","journal-title":"J Biological Chem"},{"issue":"3","key":"12941_CR6","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1086\/318804","volume":"68","author":"S Guida","year":"2001","unstructured":"Guida S, Trettel F, Pagnutti S, Mantuano E, Tottene A, Veneziano L et al (2001) Complete loss of P\/Q calcium channel activity caused by a CACNA1A missense mutation carried by patients with episodic ataxia type 2. The Am J Human Genet 68(3):759\u2013764","journal-title":"The Am J Human Genet"},{"issue":"2","key":"12941_CR7","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00415-004-0299-1","volume":"251","author":"H Harno","year":"2004","unstructured":"Harno H, Hirvonen T, Kaunisto MA, Aalto H, Levo H, Isotalo E et al (2004) Acetazolamide improves neurological abnormalities in a family with episodic ataxia type 2 (EA-2). J Neurol 251(2):232\u2013234","journal-title":"J Neurol"},{"issue":"16","key":"12941_CR8","doi-asserted-by":"publisher","first-page":"4141","DOI":"10.1523\/JNEUROSCI.0098-05.2005","volume":"25","author":"CJC Weisz","year":"2005","unstructured":"Weisz CJC, Raike RS, Soria-Jasso LE, Hess EJ (2005) Potassium channel blockers inhibit the triggers of attacks in the calcium channel mouse mutant tottering. The J Neurosci 25(16):4141\u20134145","journal-title":"The J Neurosci"},{"issue":"4","key":"12941_CR9","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s002210100788","volume":"139","author":"Y Etzion","year":"2001","unstructured":"Etzion Y, Grossman Y (2001) Highly 4-aminopyridine sensitive delayed rectifier current modulates the excitability of guinea pig cerebellar Purkinje cells. Exp Brain Res 139(4):419\u2013425","journal-title":"Exp Brain Res"},{"issue":"4","key":"12941_CR10","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1212\/CPJ.0000000000001017","volume":"11","author":"C Muth","year":"2021","unstructured":"Muth C, Teufel J, Sch\u00f6ls L, Synofzik M, Franke C, Timmann D et al (2021) Fampridine and acetazolamide in EA2 and related familial EA. Neurol Clin Pract 11(4):e438\u2013e446","journal-title":"Neurol Clin Pract"},{"issue":"9","key":"12941_CR11","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1212\/01.WNL.0000125691.74109.53","volume":"62","author":"M Strupp","year":"2004","unstructured":"Strupp M, Kalla R, Dichgans M, Freilinger T, Glasauer S, Brandt T (2004) Treatment of episodic ataxia type 2 with the potassium channel blocker 4-aminopyridine. Neurology 62(9):1623\u20131625","journal-title":"Neurology"},{"issue":"3","key":"12941_CR12","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1212\/WNL.0b013e318225ab07","volume":"77","author":"M Strupp","year":"2011","unstructured":"Strupp M, Kalla R, Claassen J, Adrion C, Mansmann U, Klopstock T et al (2011) A randomized trial of 4-aminopyridine in EA2 and related familial episodic ataxias. Neurology 77(3):269\u2013275. https:\/\/doi.org\/10.1212\/WNL.0b013e318225ab07","journal-title":"Neurology"},{"issue":"4","key":"12941_CR13","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/ana.22240","volume":"68","author":"AD Goodman","year":"2010","unstructured":"Goodman AD, Brown TR, Edwards KR, Krupp LB, Schapiro RT, Cohen R et al (2010) A phase 3 trial of extended release oral dalfampridine in multiple sclerosis. Ann Neurol 68(4):494\u2013502. https:\/\/doi.org\/10.1002\/ana.22240","journal-title":"Ann Neurol"},{"issue":"9665","key":"12941_CR14","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S0140-6736(09)60442-6","volume":"373","author":"AD Goodman","year":"2009","unstructured":"Goodman AD, Brown TR, Krupp LB, Schapiro RT, Schwid SR, Cohen R et al (2009) Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. The Lancet 373(9665):732\u2013738. https:\/\/doi.org\/10.1016\/S0140-6736(09)60442-6","journal-title":"The Lancet"},{"key":"12941_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/ana.410370302","volume":"37","author":"RC Griggs","year":"1995","unstructured":"Griggs RC, Nutt JG (1995) Episodic ataxias as channelopathies. Ann Neurol 37:285\u2013287. https:\/\/doi.org\/10.1002\/ana.410370302","journal-title":"Ann Neurol"},{"key":"12941_CR16","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1002\/mds.870010404","volume":"1","author":"ST Gancher","year":"1986","unstructured":"Gancher ST, Nutt JG (1986) Autosomal dominant episodic ataxia: a heterogeneous syndrome. Mov Disord 1:239\u2013253. https:\/\/doi.org\/10.1002\/mds.870010404","journal-title":"Mov Disord"},{"issue":"21","key":"12941_CR17","doi-asserted-by":"publisher","first-page":"7258","DOI":"10.1523\/JNEUROSCI.3582-09.2010","volume":"30","author":"K Alvi\u00f1a","year":"2010","unstructured":"Alvi\u00f1a K, Khodakhah K (2010) The therapeutic mode of action of 4-aminopyridine in cerebellar ataxia. The J Neurosci 30(21):7258\u20137268. https:\/\/doi.org\/10.1523\/JNEUROSCI.3582-09.2010","journal-title":"The J Neurosci"},{"issue":"9","key":"12941_CR18","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1002\/mds.22071","volume":"23","author":"M L\u00f6hle","year":"2008","unstructured":"L\u00f6hle M, Schrempf W, Wolz M, Reichmann H, Storch A (2008) Potassium channel blocker 4-aminopyridine is effective in interictal cerebellar symptoms in episodic ataxia type 2 \u2014 A video case report. Mov Disord 23(9):1314\u20131316. https:\/\/doi.org\/10.1002\/mds.22071","journal-title":"Mov Disord"},{"issue":"2","key":"12941_CR19","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/s00415-012-6764-3","volume":"260","author":"J Claassen","year":"2013","unstructured":"Claassen J, Teufel J, Kalla R, Spiegel R, Strupp M (2013) Effects of dalfampridine on attacks in patients with episodic ataxia type 2: an observational study. J Neurol 260(2):668\u2013669. https:\/\/doi.org\/10.1007\/s00415-012-6764-3","journal-title":"J Neurol"},{"issue":"8","key":"12941_CR20","doi-asserted-by":"publisher","first-page":"5099","DOI":"10.1007\/s10072-022-06144-2","volume":"43","author":"C Gonz\u00e1lez-Mingot","year":"2022","unstructured":"Gonz\u00e1lez-Mingot C, L\u00f3pez-Ortega R, Brieva-Ruiz L (2022) The efficacy of combining topiramate and 4-aminopyridine to reduce relapses and interictal progression in two cases of episodic ataxia type 2. Neurol Sci 43(8):5099\u20135101","journal-title":"Neurol Sci"},{"key":"12941_CR21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.brainres.2009.07.061","volume":"1294","author":"AJ Smith","year":"2009","unstructured":"Smith AJ, Tauskela JS, Stone TW, Smith RA (2009) Preconditioning with 4-aminopyridine protects cerebellar granule neurons against excitotoxicity. Brain Res 1294:165\u2013175. https:\/\/doi.org\/10.1016\/j.brainres.2009.07.061","journal-title":"Brain Res"},{"issue":"3","key":"12941_CR22","doi-asserted-by":"publisher","first-page":"e976","DOI":"10.1212\/NXI.0000000000000976","volume":"8","author":"M Dietrich","year":"2021","unstructured":"Dietrich M, Hartung HP, Albrecht P (2021) Neuroprotective properties of 4-aminopyridine. Neurol- Neuroimmunol Neuroinflamm 8(3):e976","journal-title":"Neurol- Neuroimmunol Neuroinflamm"},{"issue":"6","key":"12941_CR23","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s11064-022-03845-0","volume":"48","author":"L Shi","year":"2023","unstructured":"Shi L, Jia L, Wang Y, Xiu M, Xie J (2023) 4-Aminopyridine protects nigral dopaminergic neurons in the MPTP mouse model of Parkinson\u2019s disease. Neurochem Res 48(6):1707\u20131715. https:\/\/doi.org\/10.1007\/s11064-022-03845-0","journal-title":"Neurochem Res"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12941-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-12941-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-12941-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T17:40:19Z","timestamp":1742233219000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-12941-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["12941"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-12941-4","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]},"assertion":[{"value":"30 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"On behalf of all authors, the corresponding author states that there is no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was performed in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"205"}}